JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - MHSB

  NCT03673579

  Conditions:   Preterm Birth;   Low; Birthweight, Extremely (999 Grams or Less);   Neonatal Infection;   Satisfaction;   Stress;   Chronic Lung Disease;   Growth Acceleration;   Adverse Event
  Intervention:   Device: NICU Dashboard
  Sponsors:   Philips Healthcare;   Memorial Hospital of South Bend
  Recruiting
• A Clinical Efficacy and Safety Study of SHP607 in Preventing Chronic Lung Disease in Extremely Premature Infants

  NCT03253263

  Conditions:   Retinopathy of Prematurity (ROP);   Intraventricular Hemorrhage;   Bronchopulmonary Dysplasia;   Chronic Lung Disease of Prematurity
  Intervention:   Drug: SHP607
  Sponsor:   Shire
  Recruiting
• Families of Youth With Developmental Disabilities: A Theory-Based Intervention

  NCT03495440

  Conditions:   Family Conflict;   Marital Conflict;   Communication
  Interventions:   Behavioral: Center Sessions;   Behavioral: At-home
  Sponsor:   University of Notre Dame
  Recruiting
• Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

  NCT02527681

  Condition:   Bacterial Infections
  Intervention:   Drug: ceftobiprole
  Sponsor:   Basilea Pharmaceutica
  Recruiting
• IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

  NCT03978000

  Condition:   Necrotizing Enterocolitis
  Interventions:   Drug: IBP-9414;   Drug: Placebo
  Sponsor:   Infant Bacterial Therapeutics
  Recruiting
• A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

  NCT03959488

  Condition:   Respiratory Syncytial Virus Infections
  Interventions:   Drug: MEDI8897;   Drug: Palivizumab
  Sponsor:   MedImmune LLC
  Recruiting
• JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

  NCT03796676

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Placebo;   Drug: PF-04965842;   Drug: PF04965842
  Sponsor:   Pfizer
  Recruiting
• Long-term Antipsychotic Pediatric Safety Trial

  NCT03522168

  Condition:   Weight, Body
  Interventions:   Drug: Risperidone;   Drug: Aripiprazole
  Sponsors:   Duke University;   The Emmes Company, LLC
  Recruiting
• Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181

  Conditions:   Adult Germ Cell Tumor;   Childhood Extracranial Germ Cell Tumor;   Childhood Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Grade 2 Ovarian Teratoma;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296

  Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Intervention:   Drug: Rucaparib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

  NCT03609021

  Conditions:   Breast Carcinoma;   Estrogen Receptor Negative;   Progesterone Receptor Negative
  Interventions:   Procedure: Screening Mammography;   Procedure: Biospecimen Collection
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)- Measure Up 1

  NCT03569293

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
  Sponsor:   AbbVie
  Recruiting
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822

  Condition:   Dermatitis, Atopic
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting